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We have generated unique asymmetric liposomes with phospha-
tidylserine (PS) distributed at the outer membrane surface to re-
semble apoptotic bodies and phosphatidic acid (PA) at the inner
layer as a strategy to enhance innate antimycobacterial activity in
phagocytes while limiting the inﬂammatory response. Results
show that these apoptotic body-like liposomes carrying PA (ABL/
PA) (i) are more efﬁciently internalized by human macrophages
than by nonprofessional phagocytes, (ii) induce cytosolic Ca2+ in-
ﬂux, (iii) promote Ca2+-dependent maturation of phagolysosomes
containing Mycobacterium tuberculosis (MTB), (iv) induce Ca2+-de-
pendent reactive oxygen species (ROS) production, (v) inhibit in-
tracellular mycobacterial growth in differentiated THP-1 cells as
well as in type-1 and -2 human macrophages, and (vi) down-reg-
ulate tumor necrosis factor (TNF)-α, interleukin (IL)-12, IL-1β, IL-18,
and IL-23 and up-regulate transforming growth factor (TGF)-β
without altering IL-10, IL-27, and IL-6 mRNA expression. Also,
ABL/PA promoted intracellular killing of M. tuberculosis in bron-
choalveolar lavage cells from patients with active pulmonary tu-
berculosis. Furthermore, the treatment of MTB-infected mice with
ABL/PA, in combination or not with isoniazid (INH), dramatically
reduced lung and, to a lesser extent, liver and spleen mycobacte-
rial loads, with a concomitant 10-fold reduction of serum TNF-α,
IL-1β, and IFN-γ compared with that in untreated mice. Altogether,
these results suggest that apoptotic body-like liposomes may be
used as a Janus-faced immunotherapeutic platform to deliver po-
lar secondary lipid messengers, such as PA, into phagocytes to
improve and recover phagolysosome biogenesis and pathogen
killing while limiting the inﬂammatory response.
Host phospholipids play a critical role in the activation ofthe antimicrobial innate immune response (1). In particular,
phospholipase D (PLD) activation is necessary for intracellular
killing of pathogens induced by natural ligands, such as ATP (2,
3), and by microbial ligands, such as CpG oligodeoxynucleotides
(4). Interestingly, Mycobacterium tuberculosis (MTB), unlike the
nonpathogenic Mycobacterium smegmatis, inhibits PLD activa-
tion during phagocytosis, a process that is associated with in-
tracellular survival of the pathogen (4). PLD catalyzes the
hydrolysis of the membrane phospholipid, phosphatidylcholine,
to generate the metabolically active phosphatidic acid (PA). PA
is an important second messenger involved in multiple physio-
logical functions, including (i) the assembly and activation of
NADPH oxidase, (ii) the regulation of cytoskeleton organiza-
tion, and (iii) the modulation of the vesicular trafﬁcking and
membrane ﬁssion/fusion events, responsible for phagocytosis and
phagolysosome maturation (1, 5). MTB has been also reported
to block phagolysosome maturation by inhibiting host sphingo-
sine kinase (6) and phosphatidylinositol 3-kinase activity (7),
both involved in different steps of phagolysosome biogenesis. A
report by Anes et al. showed that different bioactive lipids, like
arachidonic acid (AA), ceramide (Cer), sphingosine (Sph),
sphingomyelin (SM), phosphatidylinositol (PI), and sphingosine
1-phosphate (S1P), promoted phagolysosome maturation and
intracellular mycobacterial killing in murine macrophages (8). In
the same context, we have previously demonstrated that lyso-
phospholipids, such as S1P and lysophosphatidic acid (LPA), (i)
promote in vitro PLD-dependent phagolysosome maturation
and PLD-dependent intracellular killing of MTB in human
macrophages (9) and type II alveolar epithelial cell line A549
(10), (ii) induce ex vivo intracellular killing of endogenous
mycobacteria in bronchoalveolar lavage cells isolated from
patients affected by tuberculosis (TB) (11, 12), and (iii) reduce in
vivo pulmonary mycobacterial burden and histopathology in
murine models of TB (9, 13).
Phospholipids may also play a critical role in cell-to-cell signal-
ing. In this context, the exposure of phosphatidylserine (PS) (14,
15), on the outer leaﬂet of plasma membrane represents one of
the most striking and consistent changes of apoptotic cells. Expo-
sure of PS plays a central role in the recognition and phagocytosis
of apoptotic bodies by macrophages (16). The functional conse-
quence of a PS-dependent recognition and ingestion of apoptotic
cells by macrophages is the release of antiinﬂammatory cytokines
and the inhibition of the production of proinﬂammatory cytokines
(17). These features have highlighted the possibility of using apo-
ptotic cells to manipulate the immune response for therapeutic
gain to reduce the immunopathology (18).
The purpose of the present study was to evaluate the possi-
bility of recovering or strengthening antibacterial innate immune
responses by providing PA, involved in phagolysosome biogenesis,
using liposomes as a vehicle. In this context, the possibility of
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engineering liposomes characterized by the expression of dif-
ferent phospholipids at the outer and inner membrane surface
has been described (19) and offers a technological platform to
asymmetrically distribute bioactive phospholipids involved in
different cell functions. On these grounds, we have generated
unique asymmetric apoptotic body-like liposomes (ABL), with PS
distributed at the outer membrane surface to resemble apoptotic
bodies, thus targeting macrophages while limiting inﬂammation,
and with PA at the inner membrane surface to simultaneously
enhance phagolysosome biogenesis-related processes. These
double-faced liposomes were tested for their potential enhancing
effect on innate immunity functions and bacterial killing.
Results
Biophysical Characterization of Liposomes. To check the asymmet-
ric distribution of phospholipids in liposome preparations, we
ﬁrst stained liposomes with Cy5-Annexin V and monitored
ﬂuorescence emission distribution on the outer surface of lipo-
some membrane by ﬂow cytometry analysis. The results show the
presence of Annexin V binding sites on the liposome surface in
ABL/PA, visualized by increased ﬂuorescence emission after
Cy5-Annexin V staining (Fig. S1A). To demonstrate the pres-
ence of PA within liposomes, ABL carrying 1-myristoyl-2-{12-
[(7-nitro-2–1,3-benzoxadiazol-4-yl)amino]lauroyl}-sn-glycero-3-
phosphate (NBD-PA) (a ﬂuorescent PA analog) were analyzed
by confocal microscopy. The results, shown in Fig. S1B, reveal
the presence of PA inside the liposome membrane. The level of
asymmetry of phospholipids is further conﬁrmed when NBD-PA
is incorporated either inside the liposome membrane (PS/NBD-
PA) or at the outer liposome surface (NBD-PA/PS) (Fig. S1C).
In the ﬁrst case, on addition of the quencher, the signal decreases
∼9% but it drops ∼65% when NBD-PA is incorporated at the
outer leaﬂet. These results demonstrate that ∼90% of NBD-PA
is conﬁned at the inner liposome surface when it is produced as
PS/NBD-PA and that ∼65% of NBD-PA is distributed at the
outer surface when it is produced as NBD-PA/PS, according to
a natural tendency exerted by PA to distribute within the lipo-
some surface (20).
The liposome’s size has been tested by using dynamic light
scattering. The mean hydrodynamic radius is reported for all of
the preparations investigated [ABL/phosphatidylcholine (PC),
PC/PC, PC/PA, and ABL/PA] in Fig. S1D. All of the samples
show a hydrodynamic radius of ∼1 μm with the exception of the
ABL/PC sample whose radius is 2.5 μm, which could reﬂect the
interaction between PS and PC that modiﬁes the thermodynamic
equilibrium by shifting the mean radius toward larger values (21).
Internalization of ABL/PA and Inhibition of Proinﬂammatory
Responses. The ability of ABL carrying NBD-PA (PS/NBD-PA)
to be phagocytosed by Phorbol 12-Myristate 13-Acetate (PMA)
differentiated THP-1 (dTHP-1) cells was analyzed by confocal
microscopy and compared with control liposomes expressing
PC at the outer leaﬂet of the liposome surface (PC/NBD-PA)
(Fig. 1). As expected the expression of PS at the outer liposome
surface (PS/NBD-PA) induces liposome internalization within
macrophages (Fig. 1A), which is signiﬁcantly enhanced, in
comparison with PC/NBD-PA liposome preparations (Fig. 1B).
In agreement, the frequency of ABL/NBD-PA liposomes phago-
cytosed by macrophages was higher than that observed with PC/
NBD-PA also if FBS was replaced by human AB+ serum (Fig.
S1E). When the uptake of ABL by dTHP-1 cells was compared
with that by alveolar epithelial A549 cells, primary monocyte-
derived macrophages (MDM), and type-1 (M1) and type-2 (M2)
macrophages, results showed that the percentage of ABL/PA
phagocytosed was signiﬁcantly higher in macrophages than in
A549 cells, with the highest phagocytic capability being exerted
by primary macrophages (Fig. 1C). Finally, the possible toxic
effect by the different liposome preparations was assessed in
terms of cell viability analyzed by trypan blue exclusion (Fig.
S2A) and 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) assay (Fig. S2B). Results show that liposomes
are not toxic because no difference in cell viability is obtained
after exposure of the cells to the different liposome preparations.
We next monitored mRNA expression of representative pro-
inﬂammatory and antiinﬂammatory cytokines by real-time PCR
in dTHP-1 cells, stimulated or not with ABL/PA. The results
expressed in Fig. 1D show that after 24 h of liposome treatment,
most proinﬂammatory cytokine mRNAs [interleukin (IL)-12-α,
IL-18, and IL-23-α] were down-regulated (−2.60-, −5.80-, and
−7.60-fold, respectively) in comparison with untreated cells
whereas IL-10, IL-27, and IL-6 mRNAs were not altered after
treatment (fold inductions between±2). By contrast, transforming
growth factor (TGF)-βmRNA was strongly up-regulated (+4.66-
fold induction) after exposure of macrophages with ABL/PA.
ABL/PA Limit Inﬂammatory Responses and Enhance Intracellular
Mycobacterial Killing in the Course of in Vitro M. tuberculosis
Infection. To evaluate proinﬂammatory vs. antiinﬂammatory
properties of ABL/PA in the course of in vitro MTB infection,
we measured the production of tumor necrosis factor (TNF)-α,
IL-1β, and TGF-β in the supernatant of dTHP-1 cells, infected or
not with MTB and in the presence or absence of liposomes, 72 h
after infection (Fig. 2A). As expected, both IL-1β and TNF-α
were strongly up-regulated after MTB infection and ABL/PA
slightly, although signiﬁcantly, reduced their release. By contrast,
TGF-β production was signiﬁcantly up-regulated in MTB-infec-
ted liposome-treated macrophages in comparison with MTB-
Fig. 1. Internalization of ABL/PA and inhibition of proinﬂammatory re-
sponse in human macrophages. (A) dTHP-1 cells were stimulated with the
same number of ABL carrying NBD-PA for 90 min and phagocytosis was
analyzed by confocal ﬂuorescence microscopy. (B) Summary of the mean
percentage ± SD of dTHP-1 cells with at least one liposome internalized over
total cells by counting ≥100 dTHP-1 cells per sample. Three different
experiments were assessed. *P = 0.003 by Student’s t test. (C) Comparative
analysis of internalization of ABL carrying NBD-PA in A549 cells, dTHP-1 cells,
monocyte-derived macrophages (MDM), type 1 macrophages (M1), and type
2 macrophages (M2). Results are expressed as mean ± SD of three inde-
pendent determinations (for A549 and dTHP-1 cells) and three different
donors (for MDM, M1, and M2 cells). (D) dTHP-1 cells were stimulated with
the same number of ABL/PA for 18 h and then analyzed by real-time PCR
for detection of cytokine mRNA levels. Values of fold induction were the
means ± SD of three independent cellular experiments, each performed by
pooling of mRNA from at least three biological replicates derived by cells
seeded in different plates.
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infected controls; a slight, but not signiﬁcant, increase in TGF-β
was observed in liposome-treated macrophages in comparison
with untreated cells.
We next tested the capability of ABL/PA to increase the my-
cobacterial killing activity of dTHP-1 cells. Results (Fig. 2B)
show a signiﬁcant reduction of intracellular mycobacterial via-
bility after treatment with ABL/PA. A lesser, although still sig-
niﬁcant, reduction of intracellular mycobacterial growth was also
observed after stimulation with liposomes expressing PC outside/
PA inside (PC/PA), in agreement with the different ability of
phagocytes to internalize these two types of liposomes (Fig. 1B).
Finally, the antimycobacterial effect was speciﬁcally induced by
PA as no effect was observed after stimulation with ABL/PC.
Altogether, these results highlight PA as the component modu-
lating the antimycobacterial function of macrophages.
ABL/PA Promote Ca2+-Dependent Phagolysosome Maturation. In-
tracellular calcium increase is required for many different signal
transduction pathways, including activation of antimycobacterial
responses (22, 23). We therefore analyzed cytosolic Ca2+ inﬂux in
dTHP-1 cells following stimulation with ABL/PA. Results show an
immediate increase of cytosolic Ca2+ after ABL/PA treatment (Fig.
3A), peaking at∼3min after stimulation (889.5 nM). Cytosolic Ca2+
after ABL/PA stimulation was almost completely inhibited by the
presence of ethylene glycol tetraacetic acid (EGTA) and 1,2-bis(2-
aminophenoxy)ethane-N,N,N′,N′-tetraacetic acid acetoxymethyl
ester (BAPTA-AM), used as extracellular and intracellular Ca2+
chelators, respectively (Fig. S3 A and B). A progressive reduction in
the peak of cytosolic Ca2+ was observed following stimulation with
ABL/PC (527.6 nM), PC/PA (122.2 nM), and PC/PC (96.3 nM)
control liposomes (Fig. S3C–E). Moreover, the results indicate that
the presence of PS on the outer liposomal surface promotes Ca2+
mobilization at 20min after stimulation whereas the presence of PA
within ABL maintained Ca2+ mobilization up to 40 min (Fig. S3F).
As MTB is known to reside in immature endosomal com-
partments sequestered from late endosomes/lysosomes (24–26),
the maturation of MTB-containing vacuoles and its dependence
on Ca2+ mobilization were investigated in cells stimulated by
ABL/PA, in the presence or absence of EGTA, or by PC/PC
control liposomes by laser scanning confocal microscopy, using
(i) Lysosomal-Associated Membrane Protein (LAMP)-1 and
LAMP-3 as markers of lysosomes/late endosomes, (ii) the aci-
dophilic dye Lysotracker Red, (iii) microtubule-associated pro-
tein light chain 3 (LC-3) as an autophagy marker, and (iv) DQ-
BSA to monitor phagolysosomal protease activity. As expected,
green ﬂuorescent phagocytosed mycobacteria resided in LAMP-
1 negative compartments (Fig. 3B), consistent with an immature
maturation state of the phagosomes. In contrast, the stimulation
with ABL/PA, but not with PC/PC control liposomes, induced
the expression of LAMP-1 in phagosomes containing MTB,
which now appeared yellow, whereas the addition of EGTA al-
most completely reversed this process. In Fig. 3C, a summary of
all percentages of MTB colocalizing in Lysotracker Red, LAMP-
1, LAMP-3, LC-3, and DQ-BSA–positive vacuoles over the total
intracellular mycobacteria is given (for representative images see
Fig. S4 A–D). The results show the signiﬁcant increase in phag-
olysosome maturation following ABL/PA stimulation and the
inhibitory effect exerted by the addition of chloroquine [for
Lysotracker Red (LTR) staining] or EGTA (for all markers
used), indicating that ABL/PA-induced phagolysosome matura-
tion was Ca2+ dependent. Moreover, the analysis of LC-3, a spe-
ciﬁc autophagic membrane marker, suggests that this process
overlaps, at least in part, with the autophagolysosome pathway
(Fig. S4C).
ABL/PA Promote Intracellular Mycobacterial Killing by a Reactive
Oxygen Species (ROS)-Dependent and Phagolysosome-Mediated
Mechanism. Phagocytes generate ROS by using superoxide-gen-
erating NADPH oxidase (NOX) family proteins, which play
pivotal roles in host defense against bacterial and fungal
pathogens (27). Following stimulation with ABL/PA, a signiﬁ-
cant increase in ROS production was observed starting from 20
min after stimulation, which remained signiﬁcantly higher in
comparison with that in control liposomes up to 40 min after
stimulation (Fig. S5A). This increase was almost completely
inhibited by the addition of polyethylene glycol-Catalase (PEG-
Cat) (Fig. S5B). Moreover, because Ca2+ mobilization is required
for phagolysosome maturation and polymerization of NADPH
oxidase occurs on maturing phagosomes (28), we tested the Ca2+
dependence of ROS production. A signiﬁcant abrogation of ROS
production was observed in the presence of the extracellular
and intracellular Ca2+ chelator EGTA and BAPTA-AM, respec-
tively (Fig. S6A).
To assess the role of ABL/PA-induced phagolysosome matu-
ration and ROS production in intracellular mycobacterial killing,
dTHP-1 cells were infected with MTB, stimulated with lip-
osomes, and then exposed to the lysosomotropic agents chloro-
quine and NH4Cl, which both increase intralysosomal pH and
are considered to be general lysosomal inhibitors. Results show
that the antimycobacterial activity increased by ABL/PA was
mediated by phagolysosome maturation and acidiﬁcation be-
cause the addition of chloroquine or NH4Cl upon ABL/PA
treatment signiﬁcantly reduced intracellular mycobacterial kill-
ing, particularly after 5 d of MTB infection (Fig. S6B). Moreover,
to assess the role of ROS in the ABL/PA-induced intracellular
mycobacterial killing, MTB-infected cells were also exposed to
Fig. 2. ABL/PA modulate proinﬂammatory response and induce in-
tracellular mycobacterial killing in human macrophages. (A) Levels of IL-1β,
TNF-α, and TGF-β were analyzed in the supernatant of dTHP-1 cells infected
or not with MTB at the MOI of 1 and stimulated or not with ABL/PA lip-
osomes at 72 h after infection and stimulation. (B) dTHP-1 cells were infected
with MTB at the MOI of 1 and then stimulated, for 3 and 5 d, with the same
amount of the following liposomes: (i) phosphatidylserine outside/phos-
phatidic acid inside (ABL/PA), (ii) phosphatidylserine outside/phosphatidyl-
choline inside (ABL/PC), (iii) phosphatidylcholine outside/phosphatidic acid
inside (PC/PA), and (iv) phosphatidylcholine outside/phosphatidylcholine in-
side (PC/PC). Results are expressed as means ± SD of triplicate values and are
representative of three separate experiments. Differences were evaluated
by Student’s t test.
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PEG-Cat, which converts hydrogen peroxide to water and oxy-
gen and thus reduces ROS activity. The results indicate that
PEG-Cat almost completely abolishes ABL/PA-induced intra-
cellular MTB killing.
ABL/PA Induce Intracellular (Myco)Bacterial Killing in Primary Type-1
and Type-2 Macrophages and in Bronchoalveolar Lavage Cells. M1
and M2 macrophages have been previously described as proin-
ﬂammatory and antiinﬂammatory macrophages (29, 30), re-
spectively, playing different roles during chronic inﬂammatory
pathologies, such as TB (31). Here, we show that stimulation
with ABL/PA determines a signiﬁcant increase in the killing of
intracellular MTB by both types of macrophages (Fig. 4A) in the
absence of any macrophage toxicity (Fig. S7 A and B). Thus, the
effect of ABL/PA is evident not only in human cell lines, but also
in primary human macrophages and different subsets thereof.
On the basis of this ﬁnding, we wanted to extend our obser-
vations to in vivo-infected human macrophages. To reproduce
the effect of ABL/PA on cells from the lungs of patients with TB,
cells isolated from bronchoalveolar lavage (BAL) of three
patients with active sputum-positive pulmonary TB (patients 1, 2,
and 3) were stimulated with ABL/PA and cultured for 3 d, and,
Fig. 3. ABL/PA promote Ca2+-mediated phagolysosome maturation in human macrophages. (A) dTHP-1 cells were incubated with 3 μM Fluo-3/AM at 37 °C
for 1 h in the dark and were stimulated with ABL/PA or PC/PC control liposomes. After stimulation, ﬂuorescence emission was continuously monitored for
20 min to determine relative alterations in intensity. (B) Confocal microscopy representative images (from three separate experiments) showing the increase
of Auramine-stained MTB (green) residing in LAMP-1–positive vacuoles (red) after stimulation with ABL/PA. To distinguish signals deriving from internalized
MTB and to avoid mycobacteria adhering on the cell surface, Auramine and LAMP-1 signals were obtained from a 3D reconstruction of images taken
throughout 1 μm of thickness inside cells. Cell morphology was visualized by differential interference contrast (DIC) and the merged images of the three
signals (Auramine/LAMP-1/DIC) were also shown. (C) Summary of the mean percentage ± SD of MTB colocalizing in acidic (Lysotracker Red-positive), LAMP-1–,
LAMP-3–, LC-3–, or DQ-BSA–positive vacuoles after stimulation with ABL/PA or PC/PC control liposomes and the reverse effect exerted by EGTA or by chloroquine,
determined by counting ≥40 phagosomes per sample. Three different experiments were assessed. *P ≤ 0.001 in comparison with MTB-infected cells.
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ﬁnally, the growth of intracellular bacteria was monitored by
colony-forming unit (cfu) count. In this setting, MTB infection of
macrophages and its effects on macrophage differentiation have
already occurred in vivo such that this assay represents a model
to measure the possible in vivo efﬁcacy of ABL/PA. Fig. 4B
shows that the treatment of BAL cells from patients 1, 2, and 3
with ABL/PA induced a strong reduction of intracellular MTB.
Interestingly, when ABL/PA were tested on BAL from a patient
with Klebsiella pneumonitis (patient 4), an almost complete
eradication of intracellular Klebsiella pneumoniae was observed,
suggesting that ABL/PA treatment is not MTB speciﬁc, but
rather increases the general killing activity of macrophages.
Therapeutic Application of ABL/PA in M. tuberculosis-Infected Mice
Reduces Mycobacterial Load and Inﬂammatory Response. To test
the possible therapeutic effect of ABL/PA in vivo, MTB-infected
mice were treated by intranasal administration of ABL/PA, oral
administration of isoniazid (INH), or a combination of both,
three times per week for 4 consecutive weeks. At the end of the
treatment, mycobacterial load in the lung, spleen, and liver was
measured as well as serum levels of TNF-α, IL-1β, IFN-γ, lactate
dehydrogenase (LDH), alanine transaminase (ALT), aspartate
transaminase (AST), and blood urea nitrogen (BUN). Fig. 5A
reports that treatment with ABL/PA alone or in combination
with INH caused at 6 wk after infection (i.e., after 4 wk of
treatment) a 100-fold reduction of pulmonary mycobacterial
load (1,100 ± 120 cfu and 2,100 ± 500 cfu, respectively), whereas
treatment with INH alone caused only a 2-fold reduction of
MTB cfu. Interestingly, opposite results were obtained in the
spleen and in the liver where ∼10-fold reduction was observed
following treatment with INH or INH plus ABL/PA and a slight
reduction, which was signiﬁcant only in the spleen, was shown
following treatment with ABL/PA only. To test the speciﬁcity of
the response, we compared the in vivo effect of ABL/PA with
Fig. 4. ABL carrying PA inhibit intracellular (myco)bacterial growth in pri-
mary type 1 (M1) and type 2 (M2) macrophages and in bronchoalveolar la-
vage (BAL) cells. (A) M1 and M2 were infected with MTB at the MOI of 1 and
then stimulated, for 3 d, with same amount of ABL carrying PA. Data are
expressed as means ± SD of triplicate values and are representative of two
separate experiments. *P = 0.00071, °P = 0.001 in comparison with MTB-
infected macrophages. (B) BAL cells from three patients infected by active
pulmonary tuberculosis (patients 1, 2, and 3) and one patient infected by
Klebsiella pneumoniae (patient 4) were stimulated in vitro with same
amount of ABL/PA. A colony-forming unit assay was performed before the
addition of ABL/PA and at 72 h after stimulation. Data are expressed as
means ± SD of the cfu performed in triplicate. *P < 0.0001 in comparison
with untreated cells, by Student’s t test.
Fig. 5. Therapeutic role of ABL/PA treatment in an experimental model of
murine tuberculosis. (A) ABL/PA were administrated intranasally three times
per week, starting from day 14 after intranasal H37Rv infection, for 4 wk in
the presence or absence of isoniazid (INH) provided in the drinking water for
the same period. Mycobacterial load of the lung, spleen, and liver is shown
as the mean of cfu ± SD obtained from six mice per group at 4 and 6 wk after
infection. *P < 0.001, **P < 0.05, #P = not signiﬁcant (NS) in comparison with
MTB-infected control mice. (B) Serum levels of TNF-α, IL-1β, and IFN-γ were
quantiﬁed at 6 wk after infection and expressed as means ± SD of values
from six mice per group. *P < 0.001, **P < 0.05, #P = NS in comparison with
MTB-infected control mice.
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control liposomes (ABL/PC, PC/PA, and PC/PC) in combination
with INH, because the combined therapy (ABL/PA plus INH)
provided the best results in terms of reduction of mycobacterial
burden. Addition of control liposomes to INH therapy did not
augment the effect of INH both in the lung and in the spleen.
On the other hand, when ABL/PA was used in combination
with INH, a 100-fold reduction of mycobacterial burden was
observed in the lung (3,800 ± 510 cfu), but, as expected, not in
the spleen (Fig. S8A).
The therapeutic effect exerted by the treatment with ABL/PA
or with ABL/PA plus INH was associated with ∼10-fold re-
duction of TNF-α, IL-1β, and IFN-γ in the serum (Fig. 5B) and
with a concomitant reduction of LDH, a nonspeciﬁc marker of
tissue toxicity, and of ALT andAST as parameters of liver toxicity,
in comparison with levels in infected untreated mice (Fig. S8B).
Blood urea nitrogen (as a measure of kidney toxicity) was found
unchanged irrespective of the different treatments (Fig. S8B).
Discussion
Liposomes are vesicles of varying size consisting of a spherical
lipid bilayer, which are useful as carriers to deliver pharmaco-
logically active agents or antigens (32), as they can protect their
cargo from the environment until controlled release occurs at the
target sites. Moreover, the possibility to asymmetrically distrib-
ute bioactive lipids through the liposome membrane provides
additional value to liposome-based therapeutic strategies be-
cause the cargo of bioactive lipids, used as unique immunomo-
dulators (33), can be preferentially delivered to speciﬁc target
cells. Here we report a unique study exploring the possibility of
using liposomes as carriers of the lipid second messenger PA,
known to activate intracellular antimycobacterial signaling (2–5,
9), to promote the antimicrobial response of phagocytes. The
preferential targeting of phagocytes is obtained by the expression
of PS at the outer leaﬂet of the liposomal membrane, which
makes the liposomes behave as apoptotic bodies.
Macrophages are the primary cells initiating granuloma for-
mation and the major cell type in most granulomas (34, 35).
Moreover, they both harbor the majority of MTB bacilli and
possess effector functions to kill these bacilli. There are a variety
of macrophage phenotypes in granulomas with various functions,
including antimycobacterial effector mechanisms, pro- and
antiinﬂammatory cytokine production, and secretion of chemo-
kines and proteins associated with tissue remodeling (29, 30).
Thus, these cells contribute to most aspects of inﬂammation and
control of infection within the granuloma. The results reported
here show that the presence of PS at the outer leaﬂet of the li-
posomal membrane makes the liposomes phagocytosed more
efﬁciently by human macrophages than by alveolar epithelial
cells. Our data also show that phagocytosis of ABL/PA is asso-
ciated with enhanced TGF-β and reduced proinﬂammatory cy-
tokine expression, such as IL-12, TNF-α, IL-1β, IL-18, and IL-23.
In this context, it has been previously shown that phagocytosis of
apoptotic bodies is associated with antiinﬂammatory responses
and resolution of inﬂammation (18, 36). The antiinﬂammatory
effects of apoptotic bodies have also been demonstrated in vivo.
Deliberate instillation of apoptotic cells into sites of local in-
ﬂammation in the lungs and peritoneal cavity increased production
of TGF-β and enhanced resolution of injury (37). Moreover,
a decrease in alveolar macrophage apoptosis is associated with
increased pulmonary inﬂammation in a murine model of pneu-
mococcal pneumonia (38), and defective clearance of apoptotic
cells in CD44 knockout mice leads to unremitting inﬂammation
following noninfectious lung injury (39). On these grounds, our
results support the hypothesis that ABL may have the potential to
limit inﬂammation also in an in vivo setting.
The dynamic interactions between MTB and human macro-
phages are central in all phases of TB, from initial infection to
active disease. A crucial feature in TB is the ability of the tu-
bercle bacilli to escape the microbicidal activities of macro-
phages and to persist as intracellular parasites. In this context,
MTB was shown to have evolved a number of mechanisms that
contribute to its intracellular survival. These include inhibition of
(i) PLD-dependent PA generation (4), (ii) Ca2+ signaling (23),
and (iii) phagolysosome maturation (40). In particular, PA is
involved in the induction of several macrophage antimicrobial
activities, such as Ca2+ mobilization and actin polymerization,
ROS production, and intracellular trafﬁcking of endocytosed
immune complexes to lysosomes (41). Moreover, PA mediates
phagolysosome maturation in the course of intracellular myco-
bacterial killing induced by natural and microbial ligands, such
as ATP (2), Sphingosine 1-phosphate (9), LPA (12), and CpG
oligodeoxinucleotide (22). In this study, we have exploited the
possibility of circumventing the reduced PLD activity caused by
MTB by providing PA directly to infected macrophages, via
asymmetric liposomes. Indeed, we ﬁnd that PA delivered in the
context of ABL promotes Ca2+ mobilization, Ca2+-dependent
phagolysosome maturation, and intracellular mycobacterial kill-
ing, the extent of which is directly related to the liposome in-
ternalization capability. The efﬁcient killing of mycobacteria by
host macrophages depends on a number of mechanisms, in-
cluding production of ROS by NOX2, which is assembled from
component subunits at the plasma or phagosomal membrane of
phagocytes (42). Interestingly, ROS generation was shown to be
essential for ABL/PA-induced antimycobacterial activity, re-
sembling the effects of 1,25-dihydroxyvitamin D(3) (43, 44). Fi-
nally, autophagy has recently been reported as a possible
mechanism concurring with intracellular MTB killing (40).
Autophagy was shown to be dependent on (i) Ca2+ mobilization,
via a phosphatidylinositol 3-phosphate–mediated process (40),
(ii) ROS generation (45), and (iii) phospholipase D activity (46).
We show here that the phagolysosome maturation process in-
duced by ABL/PA is also associated with the Ca2+-dependent
acquisition of the speciﬁc autophagic marker LC-3 in the
vacuoles containing MTB. Altogether, our ﬁndings suggest that
Ca2+ mobilization, ROS generation, and (auto)phagolysosome
maturation represent effector processes induced by ABL/PA that
concur with the intracellular killing of MTB.
Macrophages can differentiate into subsets called M1 and M2,
respectively, that exhibit distinct biological features in terms of
antimicrobial defense, cytokine production, and antigen pre-
sentation (47). In particular, M1 macrophages are characterized
as having higher expression of class II MHC, CD80, and CD86
and promoting Th1 differentiation and IFN-γ production by T
cells via the production of IL-12. Conversely, M2 macrophages,
characterized by the up-regulation of scavenger receptors and
mannose receptor and by the capability to facilitate tissue repair,
produce IL-10 and TGF-β as the prevalent antiinﬂammatory
cytokines and down-regulate Th1 responses (47). In the context
of TB, M1-dependent production of proinﬂammatory mediators
and the consequent recruitment and stimulation of T cells can
lead to tissue damage and exacerbation of disease (34). As both
M1 and M2 cells can be efﬁciently infected by mycobacteria, it is
noteworthy that stimulation with ABL/PA induced intracellular
mycobacterial killing in both types of macrophages whose bal-
ance in granulomas may be necessary to control infection and
tissue damage.
Experiments in the mouse model of TB conﬁrmed the efﬁcacy
of the asymmetric liposomes also in vivo. In fact, the combined
treatment of MTB-infected mice with ABL/PA (via the in-
tranasal route) plus INH (orally administrated) resulted in a 100-
fold reduction of mycobacterial colonies in the lung and a 10-fold
reduction in the spleen and liver. The differences in the effects
observed in the analyzed organs are likely to represent the dif-
ferent pharmacokinetics of the two compounds. In this context,
intranasally administrated ABL/PA may easily reach the lung but
may be limited in reaching spleen and liver macrophages. On the
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other hand, orally administered INH may reach all organs ana-
lyzed with the same efﬁciency. Antimycobacterial activity en-
hanced by ABL/PA is also associated with a strong reduction of
both serological proinﬂammatory cytokines and hematological
parameters of tissue cytotoxicity, so conﬁrming, in an in vivo
experimental model of murine tuberculosis, the double action
of ABL/PA.
Of additional importance and high translational relevance, we
show that ABL/PA stimulation of BAL cells from TB patients as
well as from a patient with K. pneumoniae infection induced
a signiﬁcant reduction in bacterial growth of the respective en-
dogenous intracellular pathogen. BAL cells are a mixed cell
population and comprise predominantly alveolar macrophages,
T lymphocytes, and neutrophils. In this context, the result
reported herein on BAL cells is relevant because it indicates that
ABL/PA are active in a microenvironment that mirrors that of
the infected lung. ABL/PA caused the activation of Ca2+-de-
pendent ROS generation and phagolysosome maturation and
these functions were both associated with the reduction/eradi-
cation of intracellular MTB and K. pneumoniae in BAL cells. As
expected from an innate immunity-enhancing compound, the
antimicrobial effect induced by ABL/PA does not seem to dis-
criminate between intracellular pathogens and thus may repre-
sent a unique strategy to control different microbial pathogens.
In fact, induction of ROS-mediated intracellular killing of K.
pneumoniae has been described following stimulation of alveolar
macrophages with leukotrienes (48).
In conclusion, ABL/PA may be considered as Janus-faced
liposomes, with an external surface exposing PS, resembling
apoptotic bodies and inducing efﬁcient phagocytosis accompa-
nied by the induction of antiinﬂammatory responses, and with an
inner surface containing PA to enhance the antibacterial func-
tions of innate cells. In many long-lasting infections such as TB,
the activation of an inefﬁcacious immune response may lead to
a chronic inﬂammation and consequent tissue damage. The
possibility of enhancing innate immunity to treat microbial in-
fection by a noninﬂammatory pathway has been suggested in the
past (49). The existing antibiotic regimens against tuberculosis
last 6 mo, often resulting in patient noncompliance, treatment
failure, infection relapse, and the emergence of drug resistance
(26). In this context, the use of ABL/PA may represent an ex-
ploitable immunotherapeutic strategy to simultaneously reduce
immunopathology and strengthen the innate response against
multidrug- or extensively drug-resistant (myco)bacteria.
Materials and Methods
Liposome Preparations. Asymmetric liposomes were produced according to
the Pautot et al. method to allow an asymmetric distribution of the outer and
inner phospholipids (19). In particular, to prepare the inner monolayer lipid
suspension, 2.5 mg of phospholipid and 50 mL of anhydrous dodecane
(Sigma) were placed in a 100-mL glass bottle to reach a lipid concentration
of 0.05 mg/mL. The suspension was then sonicated in a bath for 30 min and
left overnight at room temperature. The following day, 250 μL of an
aqueous solution consisting of 100 mM NaCl and 5 mM Tris Buffer, pH 7,4
was added and the solution was stirred with a magnetic stir bar for a further
3 h. To prepare the outer monolayer lipid suspension, 2.5 mg of phospho-
lipid was added to 50 mL of a 99:1 dodecane:silicone solution to get a lipid
concentration of 0.05 mg/mL. Thereafter, 2 mL of outer monolayer lipid
suspension was added over 3 mL of either PBS or RPMI 1640 in a 50-mL
plastic tube (Corning). Finally, 100 μL of the inner monolayer lipid suspension
wasadded over the 2-mL lipid phase and the sample was centrifuged at
710 × g for 10 min. After the centrifugation, liposomes were collected in the
aqueous phase, using a 5-mL syringe with a 16-gauge stainless steel needle.
The following lipids (all from Avanti Polar Lipids) were used for the prepa-
ration of the inner and outer monolayers: L-α-phosphatidylserine (PS), L-α-
phosphatidylcholine (PC), L-α-phosphatidic acid (PA), and NBD-PA. Liposomes
were then quantiﬁed by ﬂow cytometry (FACSCalibur; Becton Dickinson),
allowing quantiﬁcation of monodispersed vesicles >0.2 μm in diameter,
whereas their mean radius was analyzed by dynamic light scattering analysis
(SI Materials and Methods).
Bacteria. Pathogenic MTB H37Rv was grown in Middle Brook 7H9 broth
supplemented with albumin, dextrose, and catalase. Mycobacteria were then
harvested, suspended in sterile PBS, pH 7.2, aliquoted, and stored at −80 °C
until use. Before infection, aliquots were grown on 7H10 plates to titer the
bacteria after thawing.
Cell Cultures. The human promonocytic THP-1 leukemia cell line, induced to
differentiate by stimulation with PMA, was used as a model of human
macrophages. Cells were grown in complete medium (RPMI 1640 supple-
mented with 10% (vol/vol) FBS, 2 mM L-glutamine, and 5 μg/mL Gentamicin)
supplemented with 1 mM nonessential amino acids and 1 mM sodium py-
ruvate and incubated for 72 h at 37 °C in the presence of 20 ng/mL PMA. In
several experiments, the human lung adenocarcinoma epithelial A549 cell
line (ATCC) was used as a model of human type II alveolar epithelial cells and
cultured as described in ref. 10. Primary type 1 and type 2 macrophages were
also used as representative primary phagocytes with distinct functional ac-
tivity (50). To get M1 or M2 macrophages, peripheral blood mononuclear
cells were isolated from human buffy coat preparations and monocytes were
separated, as previously described (51). Monocytes were then suspended in
complete medium and incubated for a further 5 d in 24-well plates at the
concentration of 106 cells/mL in the absence or in the presence of 100 ng/mL
GM-CSF or 20 ng/mL M-CSF (both from R&D Systems) to get MDM, M1 and
M2, respectively. The M1 and M2 phenotype was then conﬁrmed by ELISA by
quantifying TNF-α, IL-6, and IL-10 (all from Thermo Scientiﬁc) release in the
supernatant and by ﬂow cytometry after staining with anti-CD14, anti-CD16,
and anti-CD163 monoclonal antibodies (Fig. S9 A and B) (50). dTHP-1 cells,
A549 cells, M1, and M2 were then washed and reconstituted in complete
medium, before use in experiments. In all experiments, cells were exposed to
one liposome per cell.
Infection and Evaluation of Intracellular Mycobacterial Growth. Differentiated
THP-1 (5 × 105/well) and M1 and M2 (106/well) were exposed for 3 h to MTB
H37Rv at the multiplicity of infection (MOI) of 1 in 24-well plates. After re-
moval of extracellular bacilli, cells were stimulated with phosphatidylserine
outside/phosphatidic acid inside (ABL/PA), phosphatidylserine outside/phos-
phatidylcholine inside (ABL/PC), phosphatidylcholine outside/ phosphatidic
acid inside (PC/PA), or phosphatidylcholine outside/phosphatidylcholine in-
side (PC/PC) and cfu assays were performed at days 3 and 5 postinfection, as
previously described (9). To ascertain whether phagolysosome maturation
was responsible for intracellular mycobacterial killing, 10 μM chloroquine or
20 mM NH4Cl was added to MTB-infected cells together with ABL/PA, as
described in ref. 10. Finally, the role of ROS in intracellular mycobacterial
killing was analyzed by adding 100 units/mL PEG-Catalase.
Quantiﬁcation of Cytokines by Real-Time PCR and ELISA. RNA extraction and
real-time PCR were performed as previously described (52). Brieﬂy, total RNA
was extracted from 2 × 106 cells, using RNeasy kits (Qiagen) as described by
the manufacturer, and quantiﬁed by optical density. One hundred nano-
grams of total RNA was reverse transcribed using the high-capacity cDNA
Archive Kit (Applied Biosystems) and random hexamer primers in an ABI
Prism 7000 Sequence Detector System (Applied Biosystems), using the fol-
lowing thermal proﬁle: 25 °C for 10 min, 42 °C for 1 h, and 95 °C for 5 min.
PCR reactions were performed in triplicate using TaqMan chemistry with
primer and probe sets from the Assay-on-Demand list (Applied Biosystems).
Each gene proﬁle was compared with the standard curve of the reference
and calculation of the slope of log[ng RNA] vs. ΔCt was always <0.1. Fold
induction was then calculated by ΔΔCt method (53), using the 18S mRNA
level to normalize values and the mRNA level of basal condition (unstimu-
lated dTHP-1) as a calibrator. Values of fold induction were the means ± SD
of three independent cellular experiments.
The levels of IL-1β, TNF-α, and TGF-β in the supernatant of dTHP-1 cells
infected or not with MTB at the MOI of 1 and stimulated or not with ABL/PA
were assessed by commercially available kits [human TNF-α ELISA kit and
human IL-1β ELISA kit (Thermo Scientiﬁc) and DRG TGF-β1 ELISA (DRG In-
ternational)] and used according to the manufacturer’s instructions.
Fluorimetric Analysis. The efﬁciency of liposome internalization by different
cell types (A549, dTHP-1, MDM, M1, and M2) was analyzed by comparing
ﬂuorescence emission of cells before and after 90 min exposure to ABL
carrying NBD-PA. In several experiments, the possible contribution of serum
opsonization in liposome internalizationwas investigated by exposing cells to
ABL/PA-NBD or PC/PA-NBD liposomes in the presence of complete medium
supplemented with 10% FBS or 10% AB human serum. Percentage of the
liposome internalized was calculated according to the following formula:
[ﬂuorescence arbitrary units (FAU) of cells exposed to liposome carrying
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NBD-PA − FAU of control cells)/(FAU of liposome carrying NBD-PA – FAU of
control cells] × 100.
Finally, intracellular Ca2+ was measured after labeling cells with the 3-μM
ﬂuorescent intracellular Ca2+ indicator Fluo-3/AM (Molecular Probes), as
described in ref. 10, followed by incubation at 37 °C with the different li-
posome preparations used at the ratio of one liposome per cell. The con-
centration of Ca2+ was determined from ﬂuorescence ratios, as previously
described (54).
Fluorescence emission was monitored by the use of a Perkin-Elmer LS50B
luminescence spectrometer.
Confocal Microscopy Analysis. The degree of maturation of MTB-containing
endosomes was assessed after 18 h stimulation of dTHP-1 cells with ABL/PA or
PC/PC, in presence or absence of 3 mM EGTA or 10 mM chloroquine, by
analyzing the colocalization of bacilli with lysosomes after staining the
mycobacteria with auramine and the lysosomes with (i) the acidophilic dye
Lysotracker Red (Molecular Probes) (49), (ii) Alexa Fluor 647 anti-LAMP-3
monoclonal antibody (IgG1, clone MX-49.129.5; Santa Cruz Biotechnology),
(iii) Alexa Fluor 647 anti-LAMP-1 monoclonal antibody (IgG2b, clone 25;
Transduction Laboratories, Becton Dickinson), or (iv) anti-LC3 puriﬁed rabbit
polyclonal antibody (clone name RB7481; Abgent). Brieﬂy, cells were washed
with PBS, ﬁxed by 10 min incubation with 4% paraformaldehyde at 4 °C, and
permeabilized with 0.2% Triton X-100 followed by further three washings
with PBS. The localization of MTB was determined by incubating the
infected monolayer with Auramine (Becton Dickinson) for 20 min at room
temperature, followed by 3 min incubation in 0.5% acid alcohol and re-
peated washing with PBS. Detection of the lysosomal protein markers LAMP-
1 and LAMP-3 was accomplished by 1 h incubation with speciﬁc monoclonal
antibodies, and LC3 was analyzed by 1 h incubation with a polyclonal an-
tibody stained with secondary antibody Alexa Fluor 488-conjugated anti-
rabbit IgG for 1 h (Molecular Probes). In several experiments, the cells were
incubated with 10 μg/mL DQ red BSA (Molecular Probes) for 2 h before in-
fection and for 35 min after infection, at 37 °C. Detection of the acidophilic
dye Lysotracker Red was analyzed on dTHP-1 cells infected for 3 h with MTB
expressing green ﬂuorescent protein (GFP-MTB) (55) and followed by 2 h
incubation with the acidophilic dye. Then, cells were ﬁxed and processed for
confocal microscopy as indicated above.
Finally, in several experiments the internalization of liposomes was ana-
lyzed by confocal laser scanning microscopy, using a Leica TCS-SP5 operating
system. The percentage of liposome-positive dTHP-1 cells was assessed by
counting cells incorporating at least one liposome carrying NBD-PA over the
total cells.
Efﬁcacy of ABL/PA in BAL Cells. Three (age 40 ± 10 y, 3 males) of 13 patients
enrolled for microbiological conﬁrmation of pulmonary TB, before the ini-
tiation of antimycobacterial treatment, were ﬁnally diagnosed as active
pulmonary TB with BAL culture positive for MTB. A fourth patient with
inﬁltrated upper right lobe and one calciﬁcation on the left lower lobe at
chest X-rays and BAL culture positive for ampicillin-resistant K. pneumoniae
was also enrolled. Patients gave informed consent under a study protocol
approved by the Ethics Committee of the National Institute of Infectious
Diseases “Lazzaro Spallanzani,” Rome, of the “Azienda Ospedaliera
S. Camillo-Forlanini,” Rome, and of Policlinico of “Tor Vergata,” Rome. BAL
was treated as previously described (11, 12). Brieﬂy, BAL cells were sus-
pended as 106 cells/mL in medium consisting of RPMI 1640 supplemented
with 10% FBS, 2 mM L-Glu, 5 μg/mL Gentamycin, 5 μg/mL Ampicillin, and
2 μg/mL Fluconazole (all from Invitrogen) to allow selective growth of in-
tracellular mycobacteria. Finally, 106 cells per well were incubated for 72 h in
24-well plates in the presence or absence of ABL/PA and analyzed at the time
indicated by colony-forming unit assays, as previously described (11, 12).
Mice, Infection, and Treatments. BALB/c mice (Charles River Laboratories) were
kept under speciﬁc pathogen-free conditions and used in accordance with
institutional guidelines in compliance with national and international law
and policies (56). Experiments were performed in speciﬁc pathogen-free
facilities. Six mice per group (matched for sex and age between 8 and 10 wk)
were infected (under light anesthesia) intranasally (i.n.) with 2.5 × 105 cfu of
midlog-phase MTB H37Rv in 0.02 mL of saline. Starting from day 14 after
infection and for a further 4 wk, mice received or not (i) 25 mg of INH
(Sigma) per 100 mL of drinking water; (ii) intranasal inoculation of 105 ABL/
PA, suspended in 50 μL of phosphate buffered saline, three times per week;
or (iii) the combination of both treatments. At the end of the fourth and
sixth week after infection, mice were killed, sera were collected, and tissue
bacillary load of lungs, spleens, and livers was quantiﬁed by plating serial
dilution of the lung, liver, and spleen homogenates into 7H10 agar, as de-
scribed previously (56, 57). TNF-α, IL-1β, and IFN-γ were quantiﬁed in the
sera (58) by ELISA kits (R&D Systems), used according to the manufacturer’s
instructions.
Statistical Analysis. Statistical analysis was carried out by the Graphpad Prism
3.0 software package. Comparison between groups was done using Student’s
t test. P < 0.05 was considered statistically signiﬁcant.
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